The chronic myeloid leukemia (CML) drug-treatment market is dominated by BCR-ABL tyrosine kinase inhibitors, notably imatinib (Novartis’s Gleevec; generics); these agents enable many CML patients to live a normal life span. This improvement in survival, coupled with the aging U.S. population, has increased the prevalence of CML. However, compliance issues with treatments that require lifelong use contribute significantly to drug resistance, fueling the demand for effective and safe second- and later-line therapies. In October 2021, Novartis’s Scemblix launched for the third- and later-line treatment of chronic CML. This first-in-class allosteric inhibitor of ABL/BCR-ABL1 is approved to treat chronic CML patients with the T315I mutation.
• What are the CML treatment rates across the various settings and lines of therapy?
• How are newer therapies for CML performing relative to more-established therapies?
• What are the main drivers of and key obstacles to prescribing select therapies, according to surveyed physicians?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Market covered: United States
Primary research: Survey of 103 U.S. hematologist-oncologists
Key drugs covered: Imatinib, Bosulif, Iclusig, Scemblix, Sprycel, Synribo, Tasigna